- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Lyra Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Di | Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | 56 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
| 26.04. | Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 106 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal... ► Artikel lesen | |
| 19.04. | Lyra Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.03. | Lyra Therapeutics files for $300M mixed shelf | 1 | Seeking Alpha | ||
| 22.03. | Lyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.03. | Lyra Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 21.03. | Lyra Therapeutics reports Q4 results | 1 | Seeking Alpha | ||
| 21.03. | Lyra Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.03. | Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 414 | GlobeNewswire (Europe) | -- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
| 01.03. | Lyra Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.03. | Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 192 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
| 08.01. | Lyra Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.12.23 | Lyra Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.12.23 | Lyra Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.11.23 | Lyra Therapeutics GAAP EPS of -$0.27, revenue of $544M | 3 | Seeking Alpha | ||
| 07.11.23 | Lyra Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.11.23 | Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | 252 | GlobeNewswire (Europe) | - Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhinosinusitis... ► Artikel lesen | |
| 31.08.23 | Pre-market Movers: iCoreConnect, noco-noco, Allarity Therapeutics, Lyra Therapeutics, Mainz Biomed | 893 | AFX News | PARIS (dpa-AFX) - The following is a list of some of the stocks making big moves in Thursday's pre-market trading (as of 07.55 A.M. ET).In the Green iCoreConnect Inc. (ICCT) is up over 55% at... ► Artikel lesen | |
| 12.05.23 | Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update | 295 | GlobeNewswire (Europe) | -- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-220... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,840 | -0,04 % | Märkte am Morgen: Bitcoin, AMD, Amazon, Pfizer, Vonovia, Novo Nordisk, Hugo Boss, Nordex | Der DAX ist am Dienstag rund ein Prozent tiefer bei 17.932 Punkten aus dem Handel gegangen. Heute könnte es zunächst noch ein kleines Stück weiter nach unten gehen. Die Vorgaben aus Übersee sind gemischt.... ► Artikel lesen | |
| INNOCAN PHARMA | 0,189 | +1,34 % | Biotech-Einhorn! FDA Zulassung für das CBD-Wunder?! | ||
| ASTRIA THERAPEUTICS | 9,550 | +2,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 11,900 | -1,65 % | Assembly Biosciences: CEO begeistert von "außergewöhnlichen Fortschritten" | Zusammen mit der Einladung zur Hauptversammlung am 29. Mai präsentierte Assembly Biosciences (WKN: A402CB) gestern seinen aktuellen Geschäftsbericht im Hochglanz-Format. In einem Anschreiben an Aktionäre... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 1,515 | +3,48 % | Nektar Network Begins Epoch 1 of Nektar Drops - Rewards for Ongoing Participation | ||
| SOLIGENIX | 0,405 | 0,00 % | SOLIGENIX, INC.: FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection | Provides MarVax Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval
PRINCETON, N.J., April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company)... ► Artikel lesen | |
| TALPHERA | 0,943 | +2,72 % | Talphera, Inc.: Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update | Company rebranding and corporate transformation to Talphera completed in Q1 2024
First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission... ► Artikel lesen | |
| ROCKET LAB USA | 3,690 | -0,54 % | What's Going On With Rocket Lab Shares Today? | ||
| NEUROGENE | 36,630 | +3,50 % | Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases... ► Artikel lesen | |
| BOIRON | 34,000 | +0,15 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,250 | -0,71 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis | - ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports "Soft" Topical JAK Inhibitor Approach - - ATI-1777... ► Artikel lesen | |
| MEDICINOVA | 1,340 | +24,07 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| SOLID BIOSCIENCES | 10,100 | -1,27 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
| ESSA PHARMA | 6,880 | -1,01 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,520 | +7,32 % | Aquestive stock falls amid Libervant approval, Anaphylm update |
Das Unternehmen LYRA THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 4,030 Euro und damit -12,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
